Bloodstream Infection Testing Market Analysis & Forecast: 2026-2033
The Bloodstream Infection Testing Market is estimated to be valued at USD 5,000 Mn in 2026 and is expected to reach USD 8,025 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7% from 2026 to 2033.
The Bloodstream Infection Testing Market is advancing significantly with rising applications in molecular diagnostics and personalized medicine. Moreover, expanding clinical research and tightening regulatory standards are expected to drive market growth over the forecast period. Pathogens such as bacteria and fungi are primary causes of systemic infections. Bloodstream infection testing is a commonly used diagnostic technique in the biotechnological, clinical, and biochemical industries. Bloodstream infection analyzers are utilized for quantitative analysis of pathogens present in a blood sample, which aids in the accurate characterization of infections and sepsis.
The bloodstream infection testing industry is having a revolutionary period bolstered by a number of advancing analytical factors and the adoption of sophisticated detection systems, along with high demand for particular biochemical analysis in different industries, including pharmaceuticals, clinical diagnostics, biotechnology, emergency medicine, and others. These developments have spread the capabilities of bloodstream infection analyzers and enhanced their efficiency and sensitivity as well as automation, marking a transformative phase in the market.
|
Current Event |
Description and the Impact |
|
Geopolitical and Regulatory Developments |
|
|
Technological Innovations and Advancements |
|
|
Economic and Healthcare Infrastructure Trends |
|
|
Market Dynamics and Competitive Landscape |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of technology, the conventional testing segment contributes the highest share of 56.20% in 2026 of the market driven by widespread adoption of traditional culture methods. The laboratories mainly favor these methods, as they provide a cost-effective and reliable way to identify viable pathogens. These techniques allow microbiologists to observe microbial growth and perform critical phenotypic antimicrobial susceptibility testing. Although molecular diagnostics provide results at a faster rate, their high implementation costs often limit their use to supplement testing. As a result, the proven reliability of culture-based methodology will continue to dominate the overall market as healthcare providers choose proven technologies for definitive and long-term patient management.
In terms of product type, the reagents & consumables segment contributes the highest share of 64.80% in 2026 of the market due to the recurring use in testing workflows and frequent replenishment requirements. Clinicians demand a constant supply of assay kits and blood culture bottles to manage the rising incidence of sepsis and hospital-acquired infections. Unlike diagnostic instruments that represent a single capital purchase, these materials require continuous repurchasing for every patient sample. The transition toward high-throughput automated platforms is speeding up this consumption, as these systems rely on specialized proprietary reagents. This continual demand profile ensures that reagents & consumables remain the primary revenue generator for manufacturers. They also support the daily operational needs of clinical laboratories worldwide.
In terms of test type, the conventional blood culture tests segment contributes the highest share of 34.50% in 2026 of the market due to its status as a clinical gold standard. Physicians prefer these tests as the first line of defense to confirm the presence of bacteria or fungi in patients' blood. These tests provide the necessary isolates for detailed laboratory analysis, thus helping the clinicians address the specific antibiotic treatments. The detection capabilities of these tests for a wide range of aerobic and nonaerobic organisms make them more versatile than many of the targeted molecular assays. Even with new technologies, conventional blood cultures are trusted by the medical fraternity for their broad-spectrum diagnostic ability and for clinical validation.
For instance, in January 2025, Rapid Infection Diagnostics Inc. (RID) launched BSIDx, a revolutionary microbiology platform for detecting bloodstream infections. The system requires just a button press to identify pathogens and conduct antibiotic susceptibility testing directly from positive blood cultures, thereby delivering results in under five hours.
To learn more about this report, Download Free Sample
North America has remained the dominant region with 39.20% in 2026 of the global Bloodstream Infection Testing Market over the past decade owing to its extremely advanced healthcare system and the availability of leading diagnostic manufacturers in this region. The widespread knowledge about the treatment of sepsis cases and the early adoption of rapid molecular diagnostic techniques by healthcare professionals are also contributing to the high market share generated in this region. Moreover, favorable insurance policies and rigorous government regulations about hospital infections further encourage healthcare institutions to invest in advanced testing technologies. These rising cases of chronic diseases as well as the aging population of this region also require accurate bloodstream monitoring. As a result, the region remains at the forefront of the world in terms of efficiency of diagnostics and continues its immense lead in total revenue.
For instance, in April 2025, Diasorin obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LIAISON PLEX Gram-Positive Blood Culture Assay. This completes the syndromic blood culture panel lineup on the LIAISON PLEX platform for the microbiological diagnosis of bloodstream infections.
Asia Pacific is set to become the fastest-growing region. This rapid expansion occurs because governments across the region are significantly increasing their healthcare expenditures and modernizing clinical laboratory networks. The rising economies within nations such as China and India help drive this market by ensuring that the populations have greater access to basic tests for a wide array of patients. The prevalence of infectious diseases, as well as the need to improve sepsis-related mortalities, is boosting the market. Furthermore, the local manufacturers are introducing cost-effective diagnostic platforms that cater to the specific needs of resource-limited settings. These aggressive infrastructure improvements and rising medical needs solidify the status of Asia Pacific as the most dynamic globally.
For instance, in November 2024, Indonesia’s Ministry of Health (MoH) and World Health Organization (WHO) initiated the nation’s inaugural national survey addressing antimicrobial resistance (AMR) in bloodstream infections (BSIs). This effort aligns with the WHO Global Antimicrobial Resistance and Use Surveillance System. It also functions as a key indicator for measuring progress on Sustainable Development Goals.
The US market is a highly sophisticated landscape dominated by a transition toward rapid molecular diagnostics and integrated laboratory automation. With a heavy emphasis on antimicrobial stewardship programs, hospitals are increasingly bypassing traditional culture methods in favor of technologies like multiplex PCR and metagenomic sequencing. These platforms allow clinicians to identify pathogens and genetic resistance markers within a single work shift in order to minimize the mortality rates. The high healthcare expenditure and favorable reimbursement policies are propelling the adoption of premium AI driven diagnostic tools that streamline complex laboratory workflows.
For instance, in October 2025, Scanogen Inc., a molecular diagnostics innovator focused on next-generation infectious disease detection, was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The designation applies to its rapid assay which identifies bloodstream infection pathogens from patient samples.
The China market is known for its aggressive growth strategy coupled with enormous government investment directed at promoting the modernization of the country’s healthcare infrastructure. Even though conventional blood cultures are considered the standard in many local hospitals due to cost-effectiveness considerations, the large city-based medical institutions have already started embracing automated diagnostic tools coupled with proteomics analysis. The government’s initiative towards emphasizing indigenous innovation has triggered a phenomenal increase in indigenous companies competing head-to-head against already entrenched multinational companies.
For instance, in July 2025, PHASE Scientific signed an exclusive U.S. distribution agreement with Lumos Diagnostics for FebriDx. This point-of-care (POC) test uses a single drop of blood to distinguish bacterial acute respiratory infection from non-bacterial causes in about 10 minutes.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5,000 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7% | 2033 Value Projection: | USD 8,025 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
BioMérieux SA, Becton, Dickinson and Company, AB Sciex, IRIDICA, Abbot Laboratories, Cepheid Inc., C. R. Bard, Inc., F. Hoffmann-La Roche AG, Nanoshpere, Dade Behring, AdvanDX, and Siemens Healthcare. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The bloodstream infection testing market is experiencing substantial growth with the increase in sepsis incidence across global healthcare systems. Medical facilities require fast and precise pathogen detection capabilities for managing increasing patient loads effectively. Hospital-acquired infections present substantial challenges mainly for immunocompromised patients and those undergoing complex medical procedures.
Antibiotic-resistant pathogens complicate treatment strategies. this makes timely identification critical for optimal patient outcomes. Healthcare organizations recognize that diagnostic delays has a direct impact on mortality rates and treatment costs. The rising knowledge among healthcare providers and consumers is fueling significant investment in automated blood culture systems as well as molecular diagnostic platforms.
For instance, in January 2025, Inflammatix, an innovator in host-response diagnostics, revealed that the U.S. Food and Drug Administration (FDA) approved the TriVerity™ Test System (TriVerity) for marketing. This groundbreaking molecular tool targets patients with suspected acute infection or sepsis. It provides accurate bacterial-versus-viral differentiation alongside an assessment of overall illness severity based on immune response biomarkers for quick, comprehensive clinical insights.
*Definition: The bloodstream infection testing market employs advanced diagnostic computer software and high-throughput automated instruments for the detection of life-threatening pathogens. This industry is concerned with the utilization of molecular diagnostics and automated blood culture systems for performing critical tasks such as microbial detection, identification, and antibiotic susceptibility testing with high accuracy. These platforms are essential in hospitals and reference laboratories where rapid turnaround times and diagnostic accuracy are essential for managing sepsis and improving patient outcomes. The cutting-edge engineered instruments and multiplex PCR panels assist in minimizing the risk of diagnostic errors and reducing the time to results compared to traditional manual culture methods. The demand for these solutions comes from healthcare providers, diagnostic centers, and clinical laboratories.
Share
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
